Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open-Label, Single Arm Trial for Evaluation of the Efficacy and Safety in the First Line Combination Therapy of Gemcitabine, Cisplatin and Nivolumab With Additional Pretreatment of AM80 for Urothelial Carcinoma Patients

NCT06983210 is registered in ClinicalTrials.gov with Nagoya University as lead sponsor.

NCT NCT06983210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06983210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open-Label, Single Arm Trial for Evaluation of the Efficacy and Safety in the First Line Combination Therapy of Gemcitabine, Cisplatin and Nivolumab With Additional Pretreatment of AM80 for Urothelial Carcinoma Patients
Lead sponsor
Nagoya University
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2025
Completion date
March 1, 2029
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma bladder, urothelial carcinoma of the renal pelvis and ureter, urothelial carcinoma recurrent, urothelial carcinoma urethra